”Despite a much slower economic growth of only 0.9%, the 2024 results attest that MedLife has managed to maintain its financial and operational business performance. Thanks to these results, which give us reasons for optimism, we will continue our development projects. In this regard, we have proposed to supplement the syndicated loan with 50 million euros and we hope to have it approved by shareholders in March,” stated Mihai Marcu, MedLife CEO.
Most of the MedLife Group’s business lines recorded a good performance compared to 2023. Thus, the largest increases were recorded by hospitals (38%), laboratories (28%), followed by clinics (23%) and, equally, by pharmacies and the corporate division (14%).
„Although we expect a complicated year, marked by many geopolitical challenges and the need for significant fiscal adjustments in Romania, we have taken the necessary strategic measures to perform even in a period marked by uncertainties. Moreover, in recent years, in addition to diagnostic and prophylaxis platforms, we have also developed an integrated oncology platform and top hospital services, thus offering an important range of medical services that cannot be postponed to the next economic cycle”.
Operating expenses reached RON2.58 billion, from RON2.1 billion.
At the end of 2024, MedLife had RON3 billion assets and RON2.5 billion liabilities.
The company has a RON3.2 billion capitalization.
(English version by Catalina Apostoiu)